Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

CP-MGAH22-5 Study Group

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences